Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 in advanced solid tumors
NCT02211872Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BI-2536 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Tolerated Dose at 16 weeks. Started Aug 2004; status: completed.
02
Drugs
BI-2536
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02211872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211872.